<p>Artivion, Inc.（纽约证券交易所代码：AORT - 获取免费报告）在周六创下 52 周新低，此前 Citizens Jmp 将该股票的目标价从 53.00 美元下调至 48.00 美元。Citizens Jmp 目前对该股票的评级为市场表现优于大盘。Artivion 的最低交易价格为 19.16 美元，最后交易价格为 25.3640 美元，成交量为 5,135,733 股。该股票此前收盘价为 35.42 美元。</p>
<p>AORT 已经成为其他几份研究报告的主题。华尔街 Zen 在 4 月 25 日的报告中将 Artivion 的评级从 “买入” 下调至 “持有”。Canaccord Genuity Group 在 2 月 13 日的研究报告中将 Artivion 的目标价从 51.00 美元下调至 48.00 美元，并对该股票给予 “买入” 评级。Needham &amp; Company LLC 在周五的报告中将 Artivion 的目标价从 58.00 美元下调至 44.00 美元，并对该公司给予 “买入” 评级。LADENBURG THALM/SH SH 在 4 月 10 日的研究报告中将 Artivion 的评级从 “中性” 上调至 “买入”，并设定 42.00 美元的目标价。最后，Stifel Nicolaus 在 3 月 5 日的研究报告中对 Artivion 设定了 55.00 美元的目标价。七位股票研究分析师对该股票给予了 “买入” 评级，一位分析师对该公司的股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 47.83 美元。</p>
<p><strong>获取我们对 Artivion 的最新股票分析</strong></p>
<h2>Artivion 的内部买卖</h2>
<p>在其他 Artivion 的新闻中，内部人士 John E. Davis 在 3 月 3 日（星期二）出售了 4,573 股该公司的股票，交易价格为每股平均 37.78 美元，总交易额为 172,767.94 美元。出售完成后，该内部人士直接持有 230,794 股公司股票，价值为 8,719,397.32 美元。此次交易使其持股比例减少了 1.94%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，SVP Jean F. Holloway 在 3 月 4 日（星期三）出售了 8,962 股该股票，交易价格为每股平均 38.00 美元，总交易额为 340,556.00 美元。出售完成后，该高级副总裁直接持有 185,095 股公司股票，价值为 7,033,610 美元。此次交易使其持股比例减少了 4.62%。该出售的披露信息可在 SEC 备案中找到。在过去三个月中，内部人士共出售了价值 4,977,158 美元的 133,043 股公司股票。目前，企业内部人士持有该股票的 6.30%。</p>
<h2>更多 Artivion 新闻</h2>
<p>以下是本周影响 Artivion 的主要新闻：</p>
<ul>
<li>积极情绪：Artivion 报告 2026 年第一季度收入为 1.163 亿美元，同比增长 18%，调整后的每股收益为 0.08 美元，超出分析师预期。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>积极情绪：调整后的息税折旧摊销前利润（EBITDA）增长 26%，达到 2210 万美元，显示出公司在增长过程中盈利能力的改善。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>积极情绪：FDA 批准了 NEXUS 主动脉弓系统，这一重要的监管胜利可能扩大 Artivion 的可寻址市场并支持未来的增长。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>积极情绪：Artivion 行使了收购 Endospan 的选项，这可能随着时间的推移增强其主动脉疾病产品组合。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>中性情绪：公司预计 2026 年收入为 4.8 亿至 4.96 亿美元，接近华尔街的预期，但没有重大上行惊喜。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>消极情绪：尽管本季度业绩超出预期并上调，但投资者似乎关注于股票的高估值以及缺乏重大指导惊喜，导致股价下跌。为什么 Artivion 的股票今天暴跌？</li>
<li>消极情绪：Citizens JMP 和 Needham 均下调了目标价，尽管两家公司保持了看涨评级，这可能加剧了消极情绪。Benzinga 关于下调目标价的报道</li>
</ul>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近调整了对 AORT 的持股。Vanguard Group Inc.在第四季度将其在 Artivion 的持股增加了 4.7%。Vanguard Group Inc.目前持有 3,170,089 股公司股票，价值为 144,588,000 美元，在此期间又购买了 141,030 股。摩根士丹利在第四季度将其在 Artivion 的持股增加了 0.8%。摩根士丹利目前持有 2,256,742 股公司股票，价值为 102,930,000 美元，在此期间又购买了 18,248 股。State Street Corp 在第四季度将其在 Artivion 的持股增加了 2.9%。State Street Corp 目前持有 1,584,920 股公司股票，价值为 72,288,000 美元，在上个季度又收购了 44,641 股。Fred Alger Management LLC 在第四季度将其在 Artivion 的持股增加了 4.2%。Fred Alger Management LLC 目前持有 1,372,572 股公司股票，价值为 62,603,000 美元，在上个季度又收购了 55,322 股。最后，Conestoga Capital Advisors LLC 在第一季度购买了 Artivion 的新头寸，价值约为 43,044,000 美元。机构投资者和对冲基金目前持有该公司 86.37% 的股票。</p>
<h2>Artivion 股票表现</h2>
<p>该公司的债务与股本比率为 0.49，速动比率为 2.62，流动比率为 3.53。该股票的 50 日简单移动平均为 36.50 美元，200 日简单移动平均为 41.19 美元。该股票的市值为 12.3 亿美元，市盈率为 105.69，贝塔值为 1.41。</p>
<p>Artivion（纽约证券交易所代码：AORT - 获取免费报告）最近在 5 月 7 日（星期四）发布了季度财报。公司报告每股收益（EPS）为 0.08 美元，超出分析师一致预期的 0.06 美元，超出幅度为 0.02 美元。该季度公司收入为 1.1634 亿美元，而分析师预期为 1.1569 亿美元。Artivion 的净利润率为 2.55%，股本回报率为 7.21%。该公司的季度收入同比增长 17.5%。去年同期，该公司每股收益为（0.01）美元。股票分析师预计 Artivion, Inc.在当前财政年度将发布 0.63 美元的每股收益。</p>
<h2>Artivion 公司简介</h2>
<p>（获取免费报告）</p>
<p>Artivion, Inc.（纽约证券交易所代码：AORT）是一家全球医疗技术公司，开发、制造和销售用于心脏和血管手术的可植入组织产品和外科设备。公司的产品组合包括源自人类和动物组织的生物植入物，如同种异体移植和异种移植，以及合成支架和外科胶。这些产品旨在在主动脉修复、心脏瓣膜手术和血管重建等手术中修复、加固或替换受损的心血管和胸腔组织。</p>
<p>该公司最初成立于 1984 年，名为 CryoLife，并于 2022 年初更名为 Artivion，以反映其在心血管创新方面的更广泛使命。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Artivion</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Artivion 吗？</h2>
<p>在考虑 Artivion 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Artivion 并不在其中。</p>
<p>虽然 Artivion 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AORT

<p>Artivion (NYSE:AORT) 达到了新的 52 周低点 19.16 美元，此前 Citizens JMP 将其目标价从 53 美元下调至 48 美元。该股票最后交易于 25.36 美元，较前一交易日的 35.42 美元下跌。分析师的评级各不相同，七位分析师维持 “买入” 评级，一位分析师维持 “持有” 评级。尽管 2026 年第一季度报告强劲，收入增长 18%，但由于估值担忧和分析师下调的目标价，市场情绪依然消极。内部人士的抛售也加剧了该股票的下跌</p>

<p>Artivion, Inc. (NYSE:AORT - Get Free Report) reached a new 52-week low on Saturday after Citizens Jmp lowered their price target on the stock from $53.00 to $48.00. Citizens Jmp currently has a market outperform rating on the stock. Artivion traded as low as $19.16 and last traded at $25.3640, with a volume of 5135733 shares traded. The stock had previously closed at $35.42.</p>
<div class="lb-trans"><p>Artivion, Inc.（纽约证券交易所代码：AORT - 获取免费报告）在周六创下 52 周新低，此前 Citizens Jmp 将该股票的目标价从 53.00 美元下调至 48.00 美元。Citizens Jmp 目前对该股票的评级为市场表现优于大盘。Artivion 的最低交易价格为 19.16 美元，最后交易价格为 25.3640 美元，成交量为 5,135,733 股。该股票此前收盘价为 35.42 美元。</p>
</div><p>AORT has been the subject of several other research reports. Wall Street Zen cut Artivion from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 25th. Canaccord Genuity Group decreased their target price on shares of Artivion from $51.00 to $48.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, February 13th. Needham &amp; Company LLC lowered their target price on shares of Artivion from $58.00 to $44.00 and set a &#34;buy&#34; rating for the company in a report on Friday. LADENBURG THALM/SH SH raised shares of Artivion from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $42.00 price target for the company in a research report on Friday, April 10th. Finally, Stifel Nicolaus set a $55.00 price target on shares of Artivion in a research note on Thursday, March 5th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $47.83.</p>
<div class="lb-trans"><p>AORT 已经成为其他几份研究报告的主题。华尔街 Zen 在 4 月 25 日的报告中将 Artivion 的评级从 “买入” 下调至 “持有”。Canaccord Genuity Group 在 2 月 13 日的研究报告中将 Artivion 的目标价从 51.00 美元下调至 48.00 美元，并对该股票给予 “买入” 评级。Needham &amp; Company LLC 在周五的报告中将 Artivion 的目标价从 58.00 美元下调至 44.00 美元，并对该公司给予 “买入” 评级。LADENBURG THALM/SH SH 在 4 月 10 日的研究报告中将 Artivion 的评级从 “中性” 上调至 “买入”，并设定 42.00 美元的目标价。最后，Stifel Nicolaus 在 3 月 5 日的研究报告中对 Artivion 设定了 55.00 美元的目标价。七位股票研究分析师对该股票给予了 “买入” 评级，一位分析师对该公司的股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 47.83 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Artivion</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Artivion 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at Artivion</h2>
<div class="lb-trans"><h2>Artivion 的内部买卖</h2>
</div><p>In other Artivion news, insider John E. Davis sold 4,573 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $172,767.94. Following the completion of the sale, the insider directly owned 230,794 shares in the company, valued at $8,719,397.32. The trade was a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, SVP Jean F. Holloway sold 8,962 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president directly owned 185,095 shares of the company's stock, valued at $7,033,610. The trade was a 4.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 133,043 shares of company stock valued at $4,977,158. 6.30% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Artivion 的新闻中，内部人士 John E. Davis 在 3 月 3 日（星期二）出售了 4,573 股该公司的股票，交易价格为每股平均 37.78 美元，总交易额为 172,767.94 美元。出售完成后，该内部人士直接持有 230,794 股公司股票，价值为 8,719,397.32 美元。此次交易使其持股比例减少了 1.94%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，SVP Jean F. Holloway 在 3 月 4 日（星期三）出售了 8,962 股该股票，交易价格为每股平均 38.00 美元，总交易额为 340,556.00 美元。出售完成后，该高级副总裁直接持有 185,095 股公司股票，价值为 7,033,610 美元。此次交易使其持股比例减少了 4.62%。该出售的披露信息可在 SEC 备案中找到。在过去三个月中，内部人士共出售了价值 4,977,158 美元的 133,043 股公司股票。目前，企业内部人士持有该股票的 6.30%。</p>
</div><h2>More Artivion News</h2>
<div class="lb-trans"><h2>更多 Artivion 新闻</h2>
</div><p>Here are the key news stories impacting Artivion this week:</p>
<div class="lb-trans"><p>以下是本周影响 Artivion 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Artivion reported Q1 2026 revenue of $116.3 million, up 18% year over year, and adjusted EPS of $0.08, topping analyst estimates. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan</li>
<li>Positive Sentiment: Adjusted EBITDA rose 26% to $22.1 million, showing improving profitability as the company grows. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan</li>
<li>Positive Sentiment: The FDA approved the NEXUS Aortic Arch System, a meaningful regulatory win that could expand Artivion’s addressable market and support future growth. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan</li>
<li>Positive Sentiment: Artivion exercised its option to acquire Endospan, which may strengthen its aortic disease portfolio over time. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan</li>
<li>Neutral Sentiment: The company guided 2026 revenue to $480 million-$496 million, which is near Wall Street expectations but not a major upside surprise. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan</li>
<li>Negative Sentiment: Despite the beat-and-raise style quarter, investors appear focused on the stock’s rich valuation and the lack of a major guidance surprise, contributing to the selloff. Why is Artivion stock plummeting today?</li>
<li>Negative Sentiment: Citizens JMP and Needham both lowered price targets, which may have added to the negative sentiment even though both firms kept bullish ratings. Benzinga report on lowered price targets</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Artivion 报告 2026 年第一季度收入为 1.163 亿美元，同比增长 18%，调整后的每股收益为 0.08 美元，超出分析师预期。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>积极情绪：调整后的息税折旧摊销前利润（EBITDA）增长 26%，达到 2210 万美元，显示出公司在增长过程中盈利能力的改善。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>积极情绪：FDA 批准了 NEXUS 主动脉弓系统，这一重要的监管胜利可能扩大 Artivion 的可寻址市场并支持未来的增长。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>积极情绪：Artivion 行使了收购 Endospan 的选项，这可能随着时间的推移增强其主动脉疾病产品组合。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>中性情绪：公司预计 2026 年收入为 4.8 亿至 4.96 亿美元，接近华尔街的预期，但没有重大上行惊喜。Artivion 发布 2026 年第一季度财务结果并宣布行使收购 Endospan 的选项</li>
<li>消极情绪：尽管本季度业绩超出预期并上调，但投资者似乎关注于股票的高估值以及缺乏重大指导惊喜，导致股价下跌。为什么 Artivion 的股票今天暴跌？</li>
<li>消极情绪：Citizens JMP 和 Needham 均下调了目标价，尽管两家公司保持了看涨评级，这可能加剧了消极情绪。Benzinga 关于下调目标价的报道</li>
</ul>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of AORT. Vanguard Group Inc. boosted its position in shares of Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company's stock worth $144,588,000 after buying an additional 141,030 shares during the period. Morgan Stanley raised its holdings in shares of Artivion by 0.8% during the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company's stock valued at $102,930,000 after buying an additional 18,248 shares during the period. State Street Corp lifted its position in Artivion by 2.9% during the 4th quarter. State Street Corp now owns 1,584,920 shares of the company's stock worth $72,288,000 after acquiring an additional 44,641 shares in the last quarter. Fred Alger Management LLC lifted its position in Artivion by 4.2% during the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company's stock worth $62,603,000 after acquiring an additional 55,322 shares in the last quarter. Finally, Conestoga Capital Advisors LLC purchased a new position in Artivion in the 1st quarter worth approximately $43,044,000. Institutional investors and hedge funds own 86.37% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近调整了对 AORT 的持股。Vanguard Group Inc.在第四季度将其在 Artivion 的持股增加了 4.7%。Vanguard Group Inc.目前持有 3,170,089 股公司股票，价值为 144,588,000 美元，在此期间又购买了 141,030 股。摩根士丹利在第四季度将其在 Artivion 的持股增加了 0.8%。摩根士丹利目前持有 2,256,742 股公司股票，价值为 102,930,000 美元，在此期间又购买了 18,248 股。State Street Corp 在第四季度将其在 Artivion 的持股增加了 2.9%。State Street Corp 目前持有 1,584,920 股公司股票，价值为 72,288,000 美元，在上个季度又收购了 44,641 股。Fred Alger Management LLC 在第四季度将其在 Artivion 的持股增加了 4.2%。Fred Alger Management LLC 目前持有 1,372,572 股公司股票，价值为 62,603,000 美元，在上个季度又收购了 55,322 股。最后，Conestoga Capital Advisors LLC 在第一季度购买了 Artivion 的新头寸，价值约为 43,044,000 美元。机构投资者和对冲基金目前持有该公司 86.37% 的股票。</p>
</div><h2>Artivion Stock Performance</h2>
<div class="lb-trans"><h2>Artivion 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The stock has a fifty day simple moving average of $36.50 and a two-hundred day simple moving average of $41.19. The stock has a market cap of $1.23 billion, a PE ratio of 105.69 and a beta of 1.41.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.49，速动比率为 2.62，流动比率为 3.53。该股票的 50 日简单移动平均为 36.50 美元，200 日简单移动平均为 41.19 美元。该股票的市值为 12.3 亿美元，市盈率为 105.69，贝塔值为 1.41。</p>
</div><p>Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. The company had revenue of $116.34 million for the quarter, compared to analyst estimates of $115.69 million. Artivion had a net margin of 2.55% and a return on equity of 7.21%. The business's quarterly revenue was up 17.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.01) earnings per share. Equities analysts anticipate that Artivion, Inc. will post 0.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Artivion（纽约证券交易所代码：AORT - 获取免费报告）最近在 5 月 7 日（星期四）发布了季度财报。公司报告每股收益（EPS）为 0.08 美元，超出分析师一致预期的 0.06 美元，超出幅度为 0.02 美元。该季度公司收入为 1.1634 亿美元，而分析师预期为 1.1569 亿美元。Artivion 的净利润率为 2.55%，股本回报率为 7.21%。该公司的季度收入同比增长 17.5%。去年同期，该公司每股收益为（0.01）美元。股票分析师预计 Artivion, Inc.在当前财政年度将发布 0.63 美元的每股收益。</p>
</div><h2>Artivion Company Profile</h2>
<div class="lb-trans"><h2>Artivion 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.</p>
<div class="lb-trans"><p>Artivion, Inc.（纽约证券交易所代码：AORT）是一家全球医疗技术公司，开发、制造和销售用于心脏和血管手术的可植入组织产品和外科设备。公司的产品组合包括源自人类和动物组织的生物植入物，如同种异体移植和异种移植，以及合成支架和外科胶。这些产品旨在在主动脉修复、心脏瓣膜手术和血管重建等手术中修复、加固或替换受损的心血管和胸腔组织。</p>
</div><p>Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.</p>
<div class="lb-trans"><p>该公司最初成立于 1984 年，名为 CryoLife，并于 2022 年初更名为 Artivion，以反映其在心血管创新方面的更广泛使命。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Artivion</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Artivion</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Artivion Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Artivion 吗？</h2>
</div><p>Before you consider Artivion, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Artivion 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Artivion 并不在其中。</p>
</div><p>While Artivion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Artivion 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Artivion (NYSE:AORT) Sets New 12-Month Low Following Analyst Downgrade

Market Beat

Artivion

Stifel Financial

摩根士丹利

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Artivion（NYSE:AORT）在分析师下调评级后创下 12 个月新低